Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic gastroesophageal cancer that is HER2 negative
- Your tumor has a specific gene change (ARID1A mutation) found at the time of your first diagnosis
- You have not had any prior chemotherapy, radiation, or surgery for this cancer (but surgery to remove the original tumor is allowed)
- You are able to take a combination of nivolumab (immunotherapy) and oxaliplatin-based chemotherapy, and your CPS score is 5 or higher
- You are not currently taking a statin or other cholesterol medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
This trial tests whether adding a common cholesterol-lowering drug (a statin) to standard chemotherapy before surgery can improve outcomes for people with esophageal or gastroesophageal junction cancer. The goal is to see if the statin helps shrink the tumor and reduces the chance of the cancer coming back.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Hear when a new Advanced or Metastatic Gastrooesophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.